27.07.2011 • NewsQ2 2011sales and profitsSigma-Aldrich

Sigma-Aldrich Q2 Profit Rises

Sigma-Aldrich Tuesday reported a better-than-expected rise in second-quarter profit, as demand for its specialty chemicals lifted revenues by 15% from the prior-year quarter. The company also reaffirmed its adjusted earnings outlook for the full year.

The St. Louis, Mo.-based company earned $113 million or $0.91 per share for the quarter, compared to $97 million or $0.79 per share last year.

Excluding items, adjusted earnings for the quarter were $115 million or $0.93 per share, compared to $99 million or $0.81 per share last year.

On average, 12 analysts polled by Thomson Reuters expected earnings of $0.92 per share for the quarter. Analysts' estimates typically exclude special items.

Quarterly sales rose 15% to $637 million from $554 million last year. Wall Street analysts expected revenues of $621.17 million.

On an organic basis, sales improved 6%. Among segments, Research business grew organically by 4%, led by the Asia Pacific-Latin America region. Sales for the Sigma-Aldrich Fine Chemicals business achieved organic growth of 10%, led by double-digit improvement in bioscience and high tech products.

Looking ahead to fiscal year 2011, the company reaffirmed its adjusted earnings outlook of $3.60 to $3.75 per share.

Street analysts currently expect earnings of $3.70 per share for the full year.

The company also reiterated that its organic sales growth is expected to be in the mid-single digit range for 2011.

 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.